BIOX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Bioceres Crop Solutions Corp (BIOX) is not a strong buy at this time for a beginner investor with a long-term strategy. The company's financial performance is weak, with significant revenue and net income declines, and there are no positive catalysts or strong trading signals to suggest immediate upside potential. The technical indicators and analyst sentiment also do not support a compelling entry point.
The MACD is slightly positive and expanding, but RSI is neutral at 45.45, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading below key resistance levels, with a pivot at 0.447 and support at 0.358. Overall, the technical outlook is weak.
NULL identified. No recent news or significant positive developments.
A recent court ruling against Bioceres in ongoing litigation could lead to a damaging credit sale process of its Pro Farm assets. Additionally, analysts have lowered the price target and maintained a Hold rating.
In Q2 2026, revenue dropped by -25.49% YoY to $73,674,526, and net income plummeted by -127,622.78% YoY to -$183,039,821. EPS remains negative at -2.88, and gross margin decreased by -14.47% YoY to 36%. Overall, the financial performance is poor.
Canaccord analyst Austin Moeller lowered the price target to $2 from $2.25 and maintained a Hold rating. The analyst highlighted potential operational damage from the credit sale process of Pro Farm assets.
